Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H24O5 |
Molecular Weight | 404.4551 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)=CCC1=C2OC(C)(C)C=CC2=C3OC=C(C(=O)C3=C1O)C4=CC=C(O)C=C4
InChI
InChIKey=DCTLJGWMHPGCOS-UHFFFAOYSA-N
InChI=1S/C25H24O5/c1-14(2)5-10-17-21(27)20-22(28)19(15-6-8-16(26)9-7-15)13-29-24(20)18-11-12-25(3,4)30-23(17)18/h5-9,11-13,26-27H,10H2,1-4H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16921735Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21532751 | https://www.ncbi.nlm.nih.gov/pubmed/28409880 | https://www.ncbi.nlm.nih.gov/pubmed/16826976
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16921735
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21532751 | https://www.ncbi.nlm.nih.gov/pubmed/28409880 | https://www.ncbi.nlm.nih.gov/pubmed/16826976
Osajin is the major bioactive isoflavone present in the fruit of Maclura pomifera, commonly referred to as the Osage orange. Osajin have potent cardioprotective effects in perfused rat hearts and kidney subjected to global ischemia and reperfusion. Its effects may be mediated through the inhibition of lipid peroxidation. Osajin can antagonize myocardial injury induced by I/R through inhibiting oxidative stress. Osajin had a noticeable inhibition of AChE with IC(50) values of 2.239 mM.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093865 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17662606 |
6.53 µM [IC50] | ||
Target ID: CHEMBL335 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26704263 |
23.6 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16826976
Osajin was administrated to rats orally in doses of 5, 10 and 20 mg/kg once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21532751
Three different types of human NPC cell lines: TW076 (type 1 NPC, squamous cell carcinoma, EBV negative) [49], CG1 (type 2 NPC, non-keratinizing carcinoma, EBV positive) and TW04 (type 3 NPC, undifferentiated carcinoma, EBV negative) were used for activity evaluation. y, NPC cells were seeded in 96-well plates (56103 /well) and allowed to adhere for 24 h. The medium was then substituted by a fresh one containing different concentrations (0.01–10 mM) of osajin for another 24 h. For the time-course assay, the incubation times with 5 mM of osajin were 6, 12, 24, 36 and 48 h. After incubation, 10 ml of 5 mg/ml of MTT was added to each well and incubated for 4 h at 37uC. Elution of the precipitate was performed with 100 ml of solubilization solution. Cell viability was calculated from absorption values obtained at 570 nm using an automated ELISA reader (Cape Code, UK). All experimental concentrations were performed in triplicate.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
21565
Created by
admin on Sat Dec 16 20:13:17 GMT 2023 , Edited by admin on Sat Dec 16 20:13:17 GMT 2023
|
PRIMARY | |||
|
482-53-1
Created by
admin on Sat Dec 16 20:13:17 GMT 2023 , Edited by admin on Sat Dec 16 20:13:17 GMT 2023
|
PRIMARY | |||
|
C485800
Created by
admin on Sat Dec 16 20:13:17 GMT 2023 , Edited by admin on Sat Dec 16 20:13:17 GMT 2023
|
PRIMARY | |||
|
83R5N9X74B
Created by
admin on Sat Dec 16 20:13:17 GMT 2023 , Edited by admin on Sat Dec 16 20:13:17 GMT 2023
|
PRIMARY | |||
|
m860
Created by
admin on Sat Dec 16 20:13:17 GMT 2023 , Edited by admin on Sat Dec 16 20:13:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
95168
Created by
admin on Sat Dec 16 20:13:17 GMT 2023 , Edited by admin on Sat Dec 16 20:13:17 GMT 2023
|
PRIMARY | |||
|
DTXSID10964028
Created by
admin on Sat Dec 16 20:13:17 GMT 2023 , Edited by admin on Sat Dec 16 20:13:17 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD